Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

Journal of Bone and Mineral Research

Volumn 31, Issue 1, 2016, Pages 16-35

  Adler, Robert A ^a   El Hajj Fuleihan, Ghada ^b   Bauer, Douglas C ^c   Camacho, Pauline M ^d   Clarke, Bart L ^e   Clines, Gregory A ^f   Compston, Juliet E ^g   Drake, Matthew T ^e   Edwards, Beatrice J ^h   Favus, Murray J ⁱ   Greenspan, Susan L ^j   McKinney, Ross ^k   Pignolo, Robert J ^l   Sellmeyer, Deborah E ^m  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j UNIVERSITY OF PITTSBURGH   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

more..

Author keywords

BISPHOSPHONATES; DRUG HOLIDAY; LONG TERM BISPHOSPHONATE USE; OTHER OSTEOPOROSIS THERAPIES; RISK BENEFIT

Indexed keywords

ALENDRONIC ACID; ANGIOGENESIS INHIBITOR; BAZEDOXIFENE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; LASOFOXIFENE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID; IMIDAZOLE DERIVATIVE;

BODY MASS; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; FEMUR FRACTURE; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MEDICAL SOCIETY; MEDICATION COMPLIANCE; MEDLINE; NURSING HOME PATIENT; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCORING SYSTEM; SECONDARY OSTEOPOROSIS; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVISORY COMMITTEE; AGE; CHEMICALLY INDUCED; FEMALE; FEMORAL FRACTURES; MALE; METABOLISM; SEX DIFFERENCE; SPINAL FRACTURES;

ADVISORY COMMITTEES; AGE FACTORS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; RISK FACTORS; SEX FACTORS; SPINAL FRACTURES;

EID: 84957609430     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2708     Document Type: Review

References (146)

1. Johnell O, Kanis JA., An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17 (12): 1726-33.
2. Eisman JA, Bogoch ER, Dell R, et al., ASBMR Task Force on Secondary Fracture Prevention. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012; 27 (10): 2039-46.
3. FDA. Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. 2011 [Accessed May 1, 2014]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/DrugSafetyandRiskManagementAdvisoryCommittee/ucm270958.pdf.
4. Black DM, Schwartz AV, Ensrud KE, et al., FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296 (24): 2927-38.
5. Schwartz AV, Bauer DC, Cummings SR, et al., FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010; 25 (5): 976-82.
6. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA., Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004; 75 (6): 462-8.
7. Black DM, Reid IR, Boonen S, et al., The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 7 (2): 243-54.
8. Khosla S, Burr D, Cauley J, et al., American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22 (10): 1479-91.
9. Shane E, Burr D, Abrahamsen B, et al., Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29 (1): 1-23.
10. Shane E, Burr D, Ebeling PR, et al., American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25 (11): 2267-97.
11. Dell RM, Adams AL, Greene DF, et al., Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27 (12): 2544-50.
12. Schilcher J, Michaëlsson K, Aspenberg P., Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364 (18): 1728-37.
13. Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K., Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med. 2014; 371 (10): 974-76.
14. FDA Drug Safety Communication. Ongoing safety review of oral bisphosphonates and atypical sub trochanteric femur fractures. 2011 [Accessed May 1, 2014 ]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203891.htm.
15. Whitaker M, Guo J, Kehoe T, Benson G., Bisphosphonates for osteoporosis-where do we go from here ? N Engl J Med. 2012; 366 (22): 2048-51.
16. FDA panel: Rubin R. Osteoporosis drugs need better labels. Time limits on the drugs are suggested, but how much time is yet to be determined. 2011 [Accessed July 16, 2013]. Available from: http://www.webmd.com/osteoporosis/news/20110909/fda-panel-unclear-on-osteoporosis-drug-labels.
17. Khan AA, Morrison A, Hanley DA, et al., Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30 (1): 3-23.
18. Siris ES, Harris ST, Rosen CJ, et al., Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81 (8): 1013-22.
19. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011; 49 (1): 2-19.
20. Corona T, Rivera C, Otero E, Stopp L., A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease. Clin Neuropharmacol. 1995; 18 (4): 325-32.
21. Tanaka Y., Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol. 2012; 24 (3): 319-26.
22. Watts NB, Bilezikian JP, Camacho PM, et al., American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010; 16 (6): 1016-9.
23. Compston J, Bowring C, Cooper A, et al., National Osteoporosis Guideline Group. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas. 2013; 75 (4): 392-6.
24. American Society for Bone and Mineral Research. Ethics Policy and Guidelines for Leadership of the ASBMR [Accessed November 20, 2014 ]. Available from: http://www.asbmr.org/About/PoliciesProcedures/Detail.aspx?cid=e407eef4-2166-4c8c-b75e-a42deb2ba99d.
25. Black DM, Cummings SR, Karpf DB, et al., Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348: 1535-41.
26. Black DM, Delmas PD, Eastell R, et al., Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-22.
27. Chesnut III CH, Skag A, Christiansen C, et al., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19 (8): 1241-9.
28. Harris ST, Watts NB, Genant HK, et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1996; 282 (14): 1344-52.
29. Liberman UA, Weiss SR, Bröll J, et al., Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333 (22): 1437-43.
30. McClung MR, Geusens P, Miller PD, et al., Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001; 344 (5): 333-40.
31. Reginster J, Minne HW, Sorensen OH, et al., Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):8 3-91.
32. Miller PD, Recker RR, Harris S, et al., Long-term fracture rates seen with continued ibandronate treatment: pooled analyses of DIVA and MOBILE long-term extension studies. Osteoporos Int. 2014; 25 (1): 349-57.
33. Cummings SR, Black DM, Thompson DE, et al., Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280 (24): 2077-82.
34. McNabb BL, Vittinghoff E, Schwartz AV, et al., BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res. 2013; 28 (6): 1319-27.
35. Garnero P, Hausherr E, Chapuy M, et al., Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996; 11 (10): 1531-8.
36. Black DM, Thompson DE, Bauer DC, et al., Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85: 4118-24.
37. Ensrud KE, Barrett-Connor EL, Schwartz A, et al., Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004; 19 (8): 1259-69.
38. Ravn P, Christensen JO, Baumann M, Clemmesen B., Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. Bone. 1998; 22 (5): 559-64.
39. Watts NB, Chines A, Olszynski WP, et al., Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008; 19 (3): 365-72.
40. Ebetino FH, Hogan AM, Sun S, et al., The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011; 49 (1): 20-33.
41. Leu CT, Luegmayr E, Freedman LP, Rodan GA, Reszka AA., Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone. 2006; 38 (5): 628-36.
42. Nancollas GH, Tang R, Phipps RJ, et al., Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38 (5): 617-27.
43. Russel RG, Watts NB, Ebetino FH, Rogers MJ., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19 (6): 733-59.
44. Martin KE, Yu J, Campbell HE, Abarca J, White TJ., Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates and all-cause cos. J Manag Care Pharm. 2011; 17 (8): 596-609.
45. Akehurst R, Brereton N, Ariely R, et al., The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ. 2011; 14 (1): 53-64.
46. Weycker D, Lamerato L, Schooley S, et al., Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int. 2013; 24 (4): 1483-9.
47. Imaz I, Zegarra P, González-Enríquez J, et al., Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010; 21 (11): 1943-51.
48. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W., The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin. 2006; 22 (7): 1249-56.
49. Carr AJ, Thompson PW, Cooper C., Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006; 17 (11): 1638-44.
50. Ettinger MP, Gallagher R, MacCosbe PE., Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract. 2006; 12 (5): 522-8.
51. Jones TJ, Petrella RJ, Crilly R., Determinants of persistence with weekly bisphosphonates in patients with osteoporosis. J Rheumatol. 2008; 35 (9): 1865-73.
52. Kamatari M, Koto S, Ozawa N, et al., Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007; 25 (5): 302-9.
53. Lo JC, Pressman AR, Omar MA, Ettinger B., Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17 (6): 922-8.
54. Sambrook PN, Cameron ID, Chen JS, et al., Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int. 2011; 22 (9): 2551-6.
55. Curtis JR, Yun H, Matthews R, Saag KG, Delzell E., Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken). 2012; 64 (7): 1054-60.
56. Hadji P, Felsenberg D, Amling M, Hofbauer L, Kandenwein JA, Kurth A., The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014; 25 (1): 339-47.
57. Bauer DC, Schwartz A, Palermo L, et al., Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014; 174 (8): 1263-70.
58. Cosman F, Cauley JA, Eastell R, et al., Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment ? J Clin Endocrinol Metab. 2014;99(12): 4546-54.
59. Black DM, Reid IR, Cauley JA, et al., The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015; 30 (5): 934-44.
60. Vasikaran S, Eastell R, Bruyère O, et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22 (2): 391-420.
61. Bauer DC, Black DM, Garnero P, et al., Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19 (8): 1250-8.
62. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB., Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res. 2011; 26 (7): 1662-9.
63. Delmas PD, Munoz F, Black DM, et al., Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24 (9): 1544-51.
64. Leslie WD, Lix LM., Comparison between various fracture risk assessment tools. Osteoporos Int. 2014; 25 (1): 1-21.
65. Leslie WD, Majumdar S, Lix LM, et al., Can change in FRAX score be used to "treat-to-target"? A population-based cohort study. J Bone Miner Res. 2014; 29 (5): 1074-80.
66. Leslie WD, Lix LM, Johansson H, et al., Does osteoporosis therapy invalidate FRAX for fracture prediction ? J Bone Miner Res. 2012; 27 (6): 1243-51.
67. Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE., Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int. 2009; 20 (7): 1259-66.
68. Cairoli E, Eller-Vainicher C, Ulivieri FM, et al., Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis. Osteoporos Int. 2014; 25 (4): 1401-10.
69. Carmel AS, Shieh A, Bang H, Bockman RS., The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012; 23 (10): 2479-87.
70. Peris P, Torra M, Olivares V, et al., Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone. 2011; 49 (4): 706-9.
71. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B., American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl): 2-12.
72. Tennis P, Rothman KJ, Bohn RL, et al., Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf. 2012; 21 (8): 810-7.
73. Yamashita J, McCauley LK., Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3 Suppl): 233-47.
74. Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS., The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. J Clin Endocrinol Metab. 2014; 99 (8): 2729-35.
75. Hellstein JW, Adler RA, Edwards B, et al., Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011; 142 (11): 1243-51.
76. Medication-Related Osteonecrosis of the Jaw-2014 Update-AAOMS Position Paper [Accessed June 24, 2014 ]. Available from: http://www.aaoms.org/docs/position-papers/mronj-position-paper.pdf?pdf=MRONJ-Position-Paper.
77. Denosumab (Xgeva®, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw-further measures to minimise risk. 2015 [Accessed July 25, 2015 ]. Available from: https://www.gov.uk/drug-safety-update/denosumab-xgeva-prolia-intravenous-bisphosphonates-osteonecrosis-of-the-jaw-further-measures-to-minimise-risk.
78. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S., Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015; 44 (5): 568-85.
79. Edwards BJ, Bunta AD, Lane J, et al., Bisphosphonates and nonhealing femoral fractures: analyses of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events and Reports (RADAR) project. J Bone Joint Surg Am. 2013; 95 (4): 297-307.
80. Hagen JE, Miller AN, Ott SM, et al., Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry. J Bone Joint Surg Am. 2014; 96 (22): 1905-9.
81. Oh Y, Wakabayashi Y, Kurosa Y, Fujita K, Okawa A., Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: mechanical analyses by the CT-based finite element method. Injury. 2014; 45 (11): 1764-71.
82. Paparodis R, Buehring B, Pelley EM, Binkley N., A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract. 2013; 19 (3): e 64-8.
83. Schilcher J, Aspenberg P., Atypical fracture of the femur in a patient using denosumab - a case report. Acta Orthop. 2014; 85 (1): 6-7.
84. Schneider JP, Hinshaw WB, Su C, Solow P., Atypical femur fractures: 81 individual personal histories. J Clin Endocrinol Metab. 2012; 97 (12): 4324-8.
85. Khow KS, Yong TY., Atypical femoral fracture in a patient treated with denosumab. J Bone Miner Metab. 2015; 33 (3): 355-8.
86. Suresh E, Pazianas M, Abrahamsen B., Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford). 2014; 53 (1): 19-31.
87. Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S., Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013; 28 (10): 2049-59.
88. Compston J., Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int. 2011;22(12): 2951-61.
89. Van der Meulen MC, Boskey AL., Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther. 2012; 14 (4): 220.
90. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY., Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90 (3): 1294-301.
91. Visekruna M, Wilson D, McKiernan FE., Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab. 2008; 93 (8): 2948-52.
92. Cauley JA, Chalhoub D, Kassem AM, Fuleihan Gel-H. Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol. 2014; 10 (6): 338-51.
93. Cauley JA, Wampler NS, Barnhart JM, et al., Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study. Osteoporos Int. 2008; 19 (12): 1717-23.
94. Center for Disease Control. Pedestrian safety: fact sheet. 2013 [Accessed May 1, 2014]. Available from: http://www.cdc.gov/motorvehiclesafety/pedestrian-safety/factsheet.html.
95. Center for Disease Control. Homicide rates among persons aged 10-24-United States, 1981-2010. 2013 [Accessed May 1, 2014]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6227a1.htm.
96. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373 (9678): 1849-60.
97. Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F., Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab. 2011; 96 (9): 2675-80.
98. Lampropoulou-Adamidou K, Tournis S, Balanika A, et al., Sequential treatment with teriparatide and strontium ranelate in a postmenopausal woman with atypical femoral fractures after long-term bisphosphonate administration. Hormones. 2013; 12 (4): 591-7.
99. Miyakoshi N, Aizawa T, Sasaki S, et al., Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab. 2014; 10 (6): 338-51.
100. Crandall CJ, Newberry SJ, Diamant A, et al., Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med. 2014;161(10): 711-23.
101. Murad MH, Drake MT, Mullan RJ, et al., Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2012; 97 (6): 1871-80.
102. Kendler DL, Roux C, Benhamou CL, et al., Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010; 25 (1): 72-81.
103. Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014; 58 (1): 48-54.
104. Recknor C, Czerwinski E, Bone HG, et al., Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013; 121 (6): 1291-9.
105. Amgen. Safety and efficacy study to evaluate denosumab compared with zoledronic acid in postmenopausal women with osteoporosis. 2015 [Accessed May 1, 2015 ]. Available from: https://clinicaltrials.gov/ct2/show/N CT01732770. NLM Identifier: NC T01732770.
106. Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG., Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. J Bone Miner Res. 2014; 25 (7): 1953-61.
107. Vestergaard P, Fischer L, Mele M, Mosekilde L, Christiansen P., Use of bisphosphonates and risk of breast cancer. Calcif Tissue Int. 2011; 88 (4): 255-62.
108. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG., Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate - Danish National Register Based Cohort Study. Osteoporos Int. 2012; 23 (11): 2693-701.
109. Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R., Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res. 2012; 27 (3): 679-86.
110. Hue TF, Cummings SR, Cauley JA, et al., Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med. 2014; 174 (10): 1550-7.
111. Gnant M, Mlineritsch B, Stoeger H, et al., Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analyses of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015; 26 (2): 313-20.
112. Kang JH, Keller JJ, Lin HC., A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int. 2012; 23 (10): 2551-7.
113. Pittman CB, Davis LA, Zeringue AL, et al., Myocardial infarction risk among patients with fractures receiving bisphosphonates. Mayo Clin Proc. 2014; 89 (1): 43-51.
114. Beaupre LA, Morrish DW, Hanley DA, et al., Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011; 22 (3): 983-91.
115. Bolland MJ, Grey AB, Gamble GD, Reid IR., Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab. 2010; 95 (3): 1174-81.
116. Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA., Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab. 2011; 96 (4): 1006-14.
117. Hartle JE, Tang X, Kirchner HL, et al., Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am J Kidney Dis. 2012; 59 (5): 636-44.
118. Lyles KW, Colõn-Emeric CS, Magaziner JS, et al., Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357 (18): 1799-809.
119. Perkins RM, Kirchner HL, Matsushita K, Bucaloiu ID, Norfolk E, Hartle JE., Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease. Clin J Am Soc Nephrol. 2014; 9 (4): 706-9.
120. Colõn-Emeric CS, Mesenbrink P, Lyles KW, et al., Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010; 25 (1): 91-7.
121. Giangregorio LM, Leslie WD, Program MBD., Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res. 2010; 25 (6): 1400-5.
122. Lindsay R, Silverman SL, Cooper C, et al., Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285 (3): 320-3.
123. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P., Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169, 145 cases during 1977-2001. J Bone Miner Res. 2009; 24 (7): 1299-307.
124. Schousboe JT, Fink HA, Lui LY, Taylor BC, Ensrud KE., Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture. J Bone Miner Res. 2006; 21 (10): 1557-64.
125. van Geel TA, Huntjens KM, van den Bergh JP, Dinant GJ, Geusens PP., Timing of subsequent fractures after an initial fracture. Curr Osteoporos Rep. 2010;8(3): 118-22.
126. Kanis JA, Johansson H, Oden A, et al., A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2014;19(6): 893-9.
127. Grossman JM, Gordon R, Ranganath VK, et al., American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010; 62 (11): 1515-26.
128. Lekamwasam S, Adachi JD, Agnusdei D, et al., A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012; 23 (9): 2257-76.
129. Adachi JD, Bensen WG, Brown J, et al., Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337: 382-7.
130. Reid DM, Devogelaer JP, Saag K, et al., Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009; 373 (9671): 1253-63.
131. Reid DM, Hughes RA, Laan RF, et al., Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000; 15 (6): 1006-13.
132. Saag KG, Emkey R, Schnitzer TJ, et al., Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339 (5): 292-9.
133. Saag KG, Shane E, Boonen S, et al., Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357 (20): 2028-39.
134. Saag KG, Zanchetta JR, Devogelaer JP, et al., Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009; 60 (11): 3346-55.
135. Wallach S, Cohen S, Reid DM, et al., Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67 (4): 277-85.
136. Van Staa TP, Leufkens HG, Cooper C., The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13 (10): 777-87.
137. Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES., Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. Bone. 2012; 51 (3): 383-8.
138. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD., Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009; 24 (4): 719-25.
139. FDA Product Information. Reclast (R) intravenous injection, zoledronic acid intravenous injection. Novartis Pharmaceuticals Corporation (per FDA). East Hanover, NJ, 2013.
140. Orwoll E, Ettinger M, Weiss S, et al., Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343 (9): 604-10.
141. Ringe JD, Dorst A, Faber H, Ibach K., Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004; 24 (2): 110-3.
142. Ringe JD, Faber H, Farahmand P, Dorst A., Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006; 26 (5): 427-31.
143. Boonen S, Reginster JY, Kaufman JM, et al., Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367 (18): 1714-23.
144. Safford MM, Barasch A, Curtis JR, Outman R, Saag K., Bisphosphonates and hip and nontraumatic subtrochanteric femoral fractures in the Veterans Health Administration. J Clin Rheumatol. 2014; 20 (7): 357-62.
145. Ensrud KE, Taylor BC, Peters KW, et al., Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analyses of prospective cohort study. BMJ. 2014;Jul 3 (349):g 4120.
146. Uhlig K, Leff B, Kent D, et al., A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. J Gen Intern Med. 2014; 29 (4): 670-9.